Literature DB >> 21848419

Steering vaccinomics innovations with anticipatory governance and participatory foresight.

Vural Ozdemir1, Samer A Faraj, Bartha M Knoppers.   

Abstract

Vaccinomics is the convergence of vaccinology and population-based omics sciences. The success of knowledge-based innovations such as vaccinomics is not only contingent on access to new biotechnologies. It also requires new ways of governance of science, knowledge production, and management. This article presents a conceptual analysis of the anticipatory and adaptive approaches that are crucial for the responsible design and sustainable transition of vaccinomics to public health practice. Anticipatory governance is a new approach to manage the uncertainties embedded on an innovation trajectory with participatory foresight, in order to devise governance instruments for collective "steering" of science and technology. As a contrast to hitherto narrowly framed "downstream impact assessments" for emerging technologies, anticipatory governance adopts a broader and interventionist approach that recognizes the social construction of technology design and innovation. It includes in its process explicit mechanisms to understand the factors upstream to the innovation trajectory such as deliberation and cocultivation of the aims, motives, funding, design, and direction of science and technology, both by experts and publics. This upstream shift from a consumer "product uptake" focus to "participatory technology design" on the innovation trajectory is an appropriately radical and necessary departure in the field of technology assessment, especially given that considerable public funds are dedicated to innovations. Recent examples of demands by research funding agencies to anticipate the broad impacts of proposed research--at a very upstream stage at the time of research funding application--suggest that anticipatory governance with foresight may be one way how postgenomics scientific practice might transform in the future toward responsible innovation. Moreover, the present context of knowledge production in vaccinomics is such that policy making for vaccines of the 21st century is occurring in the face of uncertainties where the "facts are uncertain, values in dispute, stakes high and decisions urgent and where no single one of these dimensions can be managed in isolation from the rest." This article concludes, however, that uncertainty is not an accident of the scientific method, but its very substance. Anticipatory governance with participatory foresight offers a mechanism to respond to such inherent sociotechnical uncertainties in the emerging field of vaccinomics by making the coproduction of scientific knowledge by technology and the social systems explicit. Ultimately, this serves to integrate scientific and social knowledge thereby steering innovations to coproduce results and outputs that are socially robust and context sensitive.

Mesh:

Substances:

Year:  2011        PMID: 21848419     DOI: 10.1089/omi.2011.0087

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  9 in total

1.  Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology.

Authors:  Panga Jaipal Reddy; Rekha Jain; Young-Ki Paik; Robin Downey; Adam S Ptolemy; Vural Ozdemir; Sanjeeva Srivastava
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-03-01

2.  What If the Influenza Vaccine Did Not Offer Such Variable Protection?

Authors:  Sarah M Bartsch; Elizabeth A Mitgang; Gail Geller; Sarah N Cox; Kelly J O'Shea; Angie Boyce; Sheryl S Siegmund; Jeffrey Kahn; Bruce Y Lee
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

3.  Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action.

Authors:  Edward S Dove; Samer A Faraj; Eugene Kolker; Vural Ozdemir
Journal:  Genome Med       Date:  2012-11-29       Impact factor: 11.117

4.  Power to the people: a wiki-governance model for biobanks.

Authors:  Edward S Dove; Yann Joly; Bartha M Knoppers
Journal:  Genome Biol       Date:  2012-05-29       Impact factor: 13.583

5.  From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and "augmented" medicine: some considerations on Salvatore Iaconesi's clinical story.

Authors:  Nicola Luigi Bragazzi
Journal:  Patient Prefer Adherence       Date:  2013-04-24       Impact factor: 2.711

6.  A Delphi Technology Foresight Study: Mapping Social Construction of Scientific Evidence on Metagenomics Tests for Water Safety.

Authors:  Stanislav Birko; Edward S Dove; Vural Özdemir
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

7.  Genomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practice.

Authors:  Gail Geller; Rachel Dvoskin; Chloe L Thio; Priya Duggal; Michelle H Lewis; Theodore C Bailey; Andrea Sutherland; Daniel A Salmon; Jeffrey P Kahn
Journal:  Genome Med       Date:  2014-11-18       Impact factor: 11.117

Review 8.  Governing Personalized Health: A Scoping Review.

Authors:  Philipp Trein; Joël Wagner
Journal:  Front Genet       Date:  2021-04-21       Impact factor: 4.599

9.  Once the rockets are up, who should care where they come down? The problem of responsibility ascription for the negative consequences of biofuel innovations.

Authors:  T H Tempels; H Van den Belt
Journal:  Springerplus       Date:  2016-03-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.